Skip to content

US · TTRX · BIOTECHNOLOGY

Turn Therapeutics Inc. (TTRX) intrinsic value and stock valuation

$8.10as of 2026-11-21 · Mkt cap 280.9M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Turn Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values TTRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TTRX’s statements →

Turn Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Westlake Village, CA 91362 turntherapeutics.com

How the business is doing

Fiscal 2023–2025, USD

Revenue
$0.00
20232025
Net income
-$-3.19M
20232025
Free cash flow
-$-2.72M
20232025
Total equity
$4.69M
20232025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2023–2025, USD
202520242023
Revenue$0.00$0.00$0.00
Operating income-$-5.86M-$-1.8M-$-2.31M
Net income-$-3.19M-$-1.77M-$-2.29M
EPSd-$-232.17K-$-131.89K-$-172.83K
Operating cash flow-$-2.56M-$-1.36M-$-1.38M
Capital expenditure-$-150K-$-100K-$-40K
Free cash flow-$-2.72M-$-1.46M-$-1.42M
Total assets$12.2M$2.05M$2.01M
Total debt$80K$120K$30K
Net debt-$-5M-$-750K-$-1.16M
Total equity$4.69M-$-180K$90K
Cash and short-term investments$5.08M$870K$1.18M
Income statement
202520242023
Revenue$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00
Research and development expenses$270K$250K$10K
Selling, general and administrative expenses$5.59M$1.55M$2.3M
Other expenses$0.00$0.00$0.00
Operating expenses$5.86M$1.8M$2.31M
Cost and expenses$5.86M$1.8M$2.31M
Interest income$30K$30K$20K
Interest expense$0.00$0.00$0.00
Depreciation and amortization$50K$50K$40K
Ebitda-$-3.14M-$-1.72M-$-2.25M
Operating income-$-5.86M-$-1.8M-$-2.31M
Total other income/expenses, net$2.66M$30K$20K
Income before tax-$-3.19M-$-1.77M-$-2.29M
Income tax expense$0.00$0.00$0.00
Net income-$-3.19M-$-1.77M-$-2.29M
Weighted average shares outstanding$13.7M$13.4M$13.3M
Weighted average diluted shares outstanding$13.7M$13.4M$13.3M
Balance sheet
202520242023
Cash and short-term investments$5.08M$870K$1.18M
Net receivables$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Total current assets$5.2M$1.1M$1.2M
Property, plant and equipment, net$0.00$120K$30K
Goodwill and intangible assets$920K$820K$770K
Long-term investments$0.00$0.00$0.00
Total non-current assets$6.97M$950K$810K
Total assets$12.2M$2.05M$2.01M
Accounts payable$2.93M$0.00$0.00
Short-term debt$50K$40K$30K
Deferred revenue$0.00$0.00$0.00
Total current liabilities$6M$710K$490K
Long-term debt$30K$80K$0.00
Deferred revenue, non-current$1.44M$1.44M$1.44M
Total non-current liabilities$1.47M$1.52M$1.44M
Capital lease obligations$80K$120K$30K
Total liabilities$7.48M$2.23M$1.93M
Common stock$0.00$0.00$0.00
Retained earnings-$-22.39M-$-19.2M-$-17.43M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00
Total equity$4.69M-$-180K$90K
Total investments$0.00$0.00$0.00
Total debt$80K$120K$30K
Net debt-$-5M-$-750K-$-1.16M
Cash flow statement
202520242023
Net income-$-3.19M-$-1.77M-$-2.29M
Depreciation and amortization$50K$50K$40K
Stock-based compensation$420K$350K$640K
Change in working capital$2.37M-$0.00$230K
Accounts receivable$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Accounts payable$2.26M$0.00$0.00
Net cash provided by operating activities-$-2.56M-$-1.36M-$-1.38M
Investments in property, plant and equipment$0.00-$-100K-$-40K
Acquisitions, net$0.00$0.00$0.00
Net cash used for investing activities-$-150K-$-100K-$-40K
Common stock issued$6.92M$1.15M$500K
Common stock repurchased$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00
Net cash used for financing activities$6.92M$1.15M$500K
Net change in cash$4.2M-$-310K-$-920K
Cash at end of period$5.08M$870K$1.18M
Operating cash flow-$-2.56M-$-1.36M-$-1.38M
Capital expenditure-$-150K-$-100K-$-40K
Free cash flow-$-2.72M-$-1.46M-$-1.42M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Turn Therapeutics Inc.

        Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.

        CEO
        Bradley E. Burnam
        Employees
        2
        Beta
        2.10

        Explore

        Frequently asked questions

        What is the intrinsic value of Turn Therapeutics Inc. (TTRX)?

        InvestorsCraft does not currently publish an intrinsic value for TTRX. How the IC value is calculated.

        Is TTRX undervalued?

        InvestorsCraft does not publish an undervaluation signal for TTRX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.